Table 2 Hazard ratios of pre- and post-menopausal breast cancer according to acrylamide intake for all participants
From: Dietary acrylamide intake and risk of breast cancer in the UK women's cohort
Model 1 a | Model 2 b | |||||||
|---|---|---|---|---|---|---|---|---|
Fifth of acrylamide intake | Range ( μ g day−1) | Cases/Total | HR | 95% CI | P trend c | HR | 95% CI | P trend c |
All breast cancers | ||||||||
1 | 0–9 | 220/6747 | 1.00 | — | 1.00 | — | ||
2 | 9–13 | 213/6748 | 0.92 | (0.74, 1.13) | 1.06 | (0.83, 1.35) | ||
3 | 13–17 | 219/6747 | 0.90 | (0.73, 1.11) | 1.05 | (0.82, 1.34) | ||
4 | 17–23 | 211/6748 | 0.92 | (0.75, 1.14) | 1.12 | (0.87, 1.45) | ||
5 | 23–150 | 218/6748 | 0.97 | (0.79, 1.19) | 1.16 | (0.88, 1.52) | ||
Trend (per 10 μg day−1) | 0.99 | (0.92, 1.06) | 0.7 | 1.08 | (0.98, 1.18) | 0.1 | ||
Premenopausal | ||||||||
1 | 0–9 | 73/2956 | 1.00 | — | 1.00 | — | ||
2 | 9–13 | 85/3032 | 1.03 | (0.7, 1.5) | 1.06 | (0.71, 1.59) | ||
3 | 13–17 | 88/3127 | 1.01 | (0.7, 1.4) | 1.15 | (0.77, 1.71) | ||
4 | 17–23 | 90/3388 | 0.95 | (0.7, 1.3) | 1.15 | (0.76, 1.73) | ||
5 | 23–150 | 102/3448 | 1.20 | (0.9, 1.7) | 1.47 | (0.96, 2.27) | ||
Trend (per 10 μg day−1) | 1.06 | (0.96, 1.17) | 0.2 | 1.18 | (1.05, 1.34) | 0.008 | ||
Postmenopausal | ||||||||
1 | 0–9 | 135/3776 | 1.00 | — | 1.00 | — | ||
2 | 9–13 | 128/3716 | 0.96 | (0.7, 1.2) | 1.06 | (0.78, 1.44) | ||
3 | 13–17 | 131/3620 | 0.95 | (0.7, 1.2) | 1.00 | (0.73, 1.38) | ||
4 | 17–23 | 121/3360 | 1.03 | (0.8, 1.3) | 1.14 | (0.82, 1.58) | ||
5 | 23–150 | 116/3300 | 0.97 | (0.7, 1.3) | 0.97 | (0.68, 1.39) | ||
Trend (per 10 μg day−1) | 0.98 | (0.90, 1.07) | 0.7 | 1.00 | (0.88, 1.14) | 0.99 | ||
